// App-Quantinova.ai

Su1276 : ?E Integrin Expression As a Predictive Biomarker for Induction of Clinical Remission by Etrolizumab: Analysis of a Phase II Trial in Moderate-to-Severely Active Ulcerative Colitis

Researchers

Presenter

  • Gaik Wei Tew

Principal Investigators

  • Daniel C. Baumgart

  • Stefan Schreiber

  • Iris Dotan

  • William Sandborn

  • Gert De Hertogh

  • John A. Kirby

  • Gert A. Van Assche

  • Paul J. Rutgeerts

  • Sharon -Byrne

  • Jeffrey Eastham-Anderson

  • Lauri Diehl

  • Jackson G. Egen

  • Severine Vermeire

  • John C. Mansfield

  • Christopher A. Lamb

  • Brian G. Feagan

  • Julian Panes

Medical Centers

  • University of California, San Diego, La Jolla, CA

  • Royal Victoria Infirmary University of Newcastle, Newcastle upon Tyne, United Kingdom

  • University of Toronto, Toronto, ON, Canada

  • Hospital Clinic Barcelona, Barcelona, Spain

  • University of Western Ontario, London, ON, Canada

  • Sackler Faculty Of Medicine, Tel-Aviv University, Tel-Aviv, Israel

  • Institute of Clinical Molecular Biology, Christian-Albrechts-University, Kiel, Germany

  • University of Leuven, KUL, Leuven, Belgium

  • Charite Medical School - Humboldt-University of Berlin, Berlin, Germany

Locations

  • Canada

  • Spain

  • Germany

  • United Kingdom

  • United States

  • Israel

  • Belgium

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • Cadherin 1

Drug/Treatment

  • Etrolizumab

Outcome

  • N/A

Study Design

  • open label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved